Anti-angiogenic treatment in breast cancer: facts, successes, failures and future perspectives

The importance of angiogenesis in the development of tumors and metastases in breast cancer is well established[1]. Interrupting this process has been considered a promising therapeutic option, initially focusing on metastatic disease[2]. The most extensively studied strategy in anti-angiogenic treatment consists of blocking the vascular endothelial growth factor (VEGF) using the monoclonal antibody bevacizumab. Bevacizumab received FDA approval for metastatic breast cancer in 2008 after it was shown to nearly double progression-free survival (PFS) in combination with chemotherapy over chemotherapy alone in the first line setting[3,4].

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iDUOmN
via IFTTT